ARCT Arcturus Therapeutics Holdings Inc.
Legal ·
Arcturus filed in the Southern District of California on September 23, 2025. Capstan Therapeutics answered with counterclaims against the company and two employees, and no trial date is set.
Operating expenses fell to $31.0 million from $46.2 million, but revenue fell by $27.3 million and the net loss was approximately $27.0 million.
The at-the-market sales agreement names Cantor Fitzgerald, Wells Fargo Securities and William Blair. As of December 22, 2025, the company had sold 1,179,201 shares under it for about $12 million.
Arcturus blamed a technical transmission error for missing the deadline on its September 30, 2025 quarterly report. The notice gives no results, and the company's 2024 annual report shows cash use rising sharply.
Arcturus says a technical transmission error caused it to miss the 5:30 PM Eastern deadline on November 10, 2025 for its quarterly report. Its commercial product is KOSTAIVE, a COVID-19 vaccine sold in Japan.
Arcturus Therapeutics is a messenger RNA medicines company focused on liver and respiratory rare diseases. Its ongoing Phase 2 studies test RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). Its platforms are STARR, a self-amplifying mRNA technology, and LUNAR, a lipid nanoparticle delivery system. Its self-amplifying mRNA COVID-19 vaccine, KOSTAIVE, is approved in Japan, the European Union and the United Kingdom, and commercial sales began in Japan in October 2024. Arcturus partnered the vaccine with CSL Seqirus for COVID-19, influenza and three other infectious diseases, and notes that CSL Limited reported an accounting write-down of approximately $430 million attributable to that collaboration. In its CF program, ARCT-032 completed dosing in the three initially planned cohorts of a Phase 2 multiple ascending dose study. In its OTC program, ARCT-810 is in a Phase 2 double-blind multiple-dose study. Arcturus also reported a Phase 1 trial of a pandemic avian influenza vaccine candidate funded by BARDA.
| Product or program | What it is | Stage |
|---|---|---|
| KOSTAIVE (ARCT-154) | Self-amplifying mRNA COVID-19 vaccine partnered with CSL Seqirus | approved in Japan, the European Union and the United Kingdom |
| ARCT-810 | RNA therapeutic for ornithine transcarbamylase deficiency | Phase 2 |
| ARCT-032 | Inhaled RNA therapeutic for cystic fibrosis | Phase 2 |
| Avian influenza sa-mRNA vaccine candidate | Self-amplifying mRNA vaccine against pandemic avian influenza, BARDA funded | Phase 1 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $82.0 million | $152.3 million |
| Research and development | $112.2 million | $195.2 million |
| Net income (loss) | -$65.8 million | -$80.9 million |
| Cash from operations | -$74.3 million | -$59.7 million |
| Cash and equivalents | $230.9 million | $237.0 million |
Our latest story on this, dated Dec 30, 2025: "Arcturus files $500,000,000 replacement shelf with $187,765,319 ATM prospectus". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 6, 2026: "Arcturus sues AbbVie and Capstan over trade secrets, and Capstan counterclaims". The story links the filing or release it is based on. Read the story.
Arcturus Therapeutics Holdings Inc. trades under the ticker ARCT on NASDAQ.
Arcturus Therapeutics Holdings Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Arcturus Therapeutics Holdings Inc. is 1768224. Its filings are on SEC EDGAR.
28,423,069 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Arcturus Therapeutics Holdings Inc. under United States.
Our directory classifies Arcturus Therapeutics Holdings Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Arcturus Therapeutics Holdings Inc. is US03969T1097.
aibio.space lists Arcturus Therapeutics Holdings Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Arcturus Therapeutics is a messenger RNA medicines company focused on liver and respiratory rare diseases. Its ongoing Phase 2 studies test RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF).
KOSTAIVE (ARCT-154): Self-amplifying mRNA COVID-19 vaccine partnered with CSL Seqirus Stage: approved in Japan, the European Union and the United Kingdom.
ARCT-810: RNA therapeutic for ornithine transcarbamylase deficiency Stage: Phase 2.
$82.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,5.02,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio